7-day roundup
The 10 most notable cure or vaccine studies from the last week.
A phase 3 trial testing an RSV vaccine in pregnant women to protect infants from severe RSV, with a focus on safety and preterm birth risk.
Read lead report →Phase 3 trial testing a tetravalent inactivated enterovirus vaccine to prevent hand-foot-mouth disease and herpangina in children aged 6-71 months.
Read report →A pilot study testing a personalized neoantigen cancer vaccine for untreated CLL patients, with or without cyclophosphamide or pembrolizumab.
Read report →This study tested the MenBVac vaccine's ability to protect children against a specific meningitis B strain. It measured immune response after the fourth dose.
Read report →A phase 3 trial testing a 13-valent pneumococcal vaccine in healthy infants in China. See safety and immune response results.
Read report →This study tests a new pertussis vaccine in pregnant women to see if it safely protects Thai infants from tetanus, diphtheria, and whooping cough.
Read report →This study checked how long protection lasts from an EV71 vaccine in healthy infants and children. No new vaccine was given.
Read report →A phase 1 trial testing a new shingles vaccine for safety and immune response in adults 40 and older. Placebo-controlled and blinded.
Read report →A phase 3 study testing an investigational chickenpox vaccine in healthy toddlers aged 12-15 months, comparing safety to the approved Varivax vaccine.
Read report →A completed Phase 1 trial testing a therapeutic hepatitis B vaccine in healthy volunteers. Assessed safety and immune response.
Read report →